Transplantation proceedings · 2026
The Outcomes of Single-unit Unrelated Umbilical Cord Blood Transplantation for Adult Acute Myeloid Leukemia with RUNX1::RUNX1T1 in Multicenter Retrospective analysis.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sakurai Kazuki, Yokoyama Hisayuki, Komatsu Hiroka, Takenaka Kenta, Narumi Yoshihiro, Hatta Shunsuke, Onodera Koichi, Fukuhara Noriko, Onishi Yasushi, Katsuoka Yuna, Saito Yo, Kamata Mayumi, Harazaki Yoriko, Tomiya Yasuo, Izumi Toru, Sasaki Osamu, Harigae Hideo
Аннотация
BACKGROUND: Acute myeloid leukemia (AML) with RUNX1::RUNX1T1 usually has a favorable outcome. However, it sometimes relapses and is refractory; in these cases, allogeneic hematopoietic stem cell transplantation (HSCT) is indicated. When HLA-matched sibling donors (MSDs) are unavailable, alternative donor sources, such as unrelated umbilical cord blood cells (UCB), are considered. However, the outcomes of UCB for AML with RUNX1::RUNX1T1 have not yet been fully examined. We retrospectively analyzed the outcomes of HSCT with UCB.
METHODS: A total of 12 patients with AML with RUNX1::RUNX1T1 who received UCB transplantation between 2002 and 2022 in 3 transplantation centers in Miyagi Prefecture were included. The median age at transplantation was 32 years; ten patients chose myeloablative conditioning regimens, and 9 patients achieved complete remission just before HSCT.
RESULTS: The 3-year overall survival and relapse-free survival were both 75.0%. All patients in complete remission (CR) before HSCT remained in remission during follow-up. The cumulative incidence of 3-year non-relapse mortality was 16.7%.
CONCLUSION: These results indicate that UCB transplantation could be a feasible option for patients with relapse/refractory RUNX1::RUNX1T1-positive AML without MSDs.
METHODS: A total of 12 patients with AML with RUNX1::RUNX1T1 who received UCB transplantation between 2002 and 2022 in 3 transplantation centers in Miyagi Prefecture were included. The median age at transplantation was 32 years; ten patients chose myeloablative conditioning regimens, and 9 patients achieved complete remission just before HSCT.
RESULTS: The 3-year overall survival and relapse-free survival were both 75.0%. All patients in complete remission (CR) before HSCT remained in remission during follow-up. The cumulative incidence of 3-year non-relapse mortality was 16.7%.
CONCLUSION: These results indicate that UCB transplantation could be a feasible option for patients with relapse/refractory RUNX1::RUNX1T1-positive AML without MSDs.